Saxenda vs Wegovy
Change comparisonSaxenda contains liraglutide. Wegovy contains semaglutide. Compare approved uses, formulations, and self-pay prices.
| Compare | Saxenda | Wegovy |
|---|---|---|
| Active ingredient | LiraglutideGLP-1 | SemaglutideGLP-1 |
| How it is taken | Injection Once daily | Injection Once weekly Tablet Once daily, on an empty stomach |
| Manufacturer | Novo Nordisk | Novo Nordisk |
What was actually compared
No direct trial comparing these exact brands is included in our reviewed catalog. Results from separate trials are not a direct comparison of these products.
Weight-loss results by formulation
Each result belongs to its named trial and dose. Separate trials have different participants and methods; these figures are not a direct comparison.
| Compare | Saxenda | Wegovy |
|---|---|---|
| Injection evidence | −8% (-8.0% at 56 wks · SCALE Obesity · 3.0 mg daily (Saxenda)) SCALE Obesity · -8.0% at 56 wks 3.0 mg daily (Saxenda) Analysis not classified; see trial methods | −14.9% (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy)) STEP 1 · -14.9% at 68 wks 2.4 mg weekly (Wegovy) Accounts for treatment discontinuation |
| Tablet evidence | No reviewed weight-loss result for this brand and formulation. | −13.6% (-13.6% at 64 wks · OASIS 4 · 25 mg daily (Wegovy tablet)) OASIS 4 · -13.6% at 64 wks 25 mg daily (Wegovy tablet) Accounts for treatment discontinuation |
Entry price and maintenance price
Self-pay quotes, not insurance estimates. Each figure identifies the product, provider, and dose where published.
| Compare | Saxenda | Wegovy |
|---|---|---|
| Injection prices | Advertised entry price No product-specific quote tracked. Published maintenance dose No dose-specific quote tracked. | Advertised entry price $199/fill initially≈ $213.21 per 30 days at this quoted rate Offer through Checked Wegovy pen (standard doses 0.25-2.4 mg) NovoCare (Novo Nordisk) · Manufacturer direct first two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026 Price conditionsfirst two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026 After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply. 28-day supply Published maintenance dose $349/28 days≈ $373.93 per 30 days at this quoted rate Checked At 2.4 mg Wegovy pen (standard doses 0.25-2.4 mg) NovoCare (Novo Nordisk) · Manufacturer direct Published price at 2.4 mg Price conditionsPublished price at 2.4 mg After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply. One price for every standard dose (0.25-2.4 mg). 28-day supply |
| Tablet prices | No reviewed tablet formulation in this brand record. | Advertised entry price from $149/mo$149 per 30 days at this quoted rate Checked Wegovy pill (oral semaglutide) NovoCare (Novo Nordisk) · Manufacturer direct self-pay cash, lowest dose (1.5 mg) Price conditionsself-pay cash, lowest dose (1.5 mg) $149/mo for 1.5 mg; $199 for 4 mg (the 4 mg $149 promo ended Aug 31, 2026); $299 for 9 mg and 25 mg. 30-day supply Published maintenance dose $299/mo$299 per 30 days at this quoted rate Checked At 25 mg Wegovy pill (oral semaglutide) NovoCare (Novo Nordisk) · Manufacturer direct Published price at 25 mg Price conditionsPublished price at 25 mg $149/mo for 1.5 mg; $199 for 4 mg (the 4 mg $149 promo ended Aug 31, 2026); $299 for 9 mg and 25 mg. $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg). 30-day supply |
How these quotes are selected
For each price basis, we prefer a recently checked manufacturer-direct quote, then a recently checked provider quote for that brand and formulation. Within each group, documented 30-day costs come first, lowest to highest. Quotes without a documented supply period have no cost rank. Older quotes appear as dated references only when no current quote is tracked. Providers may differ between entry and maintenance prices. Missing maintenance prices are never replaced with entry prices. Compounded products, combined brand quotes, and membership-only fees are excluded. Prices at different doses are not equivalent treatment costs; confirm supply length, eligibility, and added fees.
Every cash quote was checked on or after . Each quote shows its own check date. A quoted maintenance dose is not a dosing recommendation. Our methodology
Approved uses by formulation
Eligibility, contraindications, and warnings are in each product's full prescribing information.
| Compare | Saxenda | Wegovy |
|---|---|---|
| Injection | Weight management in adults and children 12+ with obesity and body weight over 60 kg; adults with overweight and a weight-related condition. US prescribing information (Saxenda Injection prescribing information)Reviewed Sep 22, 2026 | Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular risk reduction in eligible adults; noncirrhotic MASH with moderate to advanced liver fibrosis in adults (accelerated approval). US prescribing information (Wegovy Injection prescribing information)Reviewed Sep 6, 2026 |
| Tablet | No reviewed tablet label in this brand record. Ingredient record | Weight management and cardiovascular risk reduction in eligible adults. The tablet is not labeled for MASH or pediatric use. US prescribing information (Wegovy Tablet prescribing information)Reviewed Sep 6, 2026 |